The theme report of the 4th Psoriasis Conference is brilliant, focusing on the frontiers and development of psoriasis.

On the morning of October 23, 2020, following the opening ceremony of the 4th Psoriasis Conference, well-known psoriasis experts at home and abroad made a keynote report on the latest experience of psoriasis prevention and treatment, the general situation of psoriasis prevention and control, and the relevant scientific research achievements of the Psoriasis mechanism.
first half of the conference was co-chaired by Professor Zheng Jie of Shanghai Jiaoda University Hospital and Professor Sun Liangdan of Anhui Medical University First Affiliated Hospital.
Professor Wang Gang from Xijing Skin Hospital of the Fourth Military Medical University first introduced the mechanism study of the functional defects of regulatory T cells and the development of psoriasis, expounded the effect of IL-17A on the immunosuppression of psoriasis regulatory T-cells, and explained in detail the role of IL-17A in the pathogenesis of psoriasis.
Professor Xu Jinhua of Huashan Hospital, affiliated with Fudan University, shared the evaluation of the effectiveness of MTX(methotrexate) in the treatment of psoriasis and the monitoring and prevention of toxic side effects in the course of its use, which brought "Huashan experience" to our clinical use of MTX.
Professor Zheng Min of the Second Hospital affiliated with Zhejiang University School of Medicine suggested that we should combine transcriptional, proteomics and extracellular vesicle MiRNA studies in the course of biologics treatment to find new biomarkers for the individual treatment of psoriasis.
Professor Chen Xiang from Xiangya Hospital, affiliated with Central South University, shared the risk factors and targets of immuno-related skin diseases, introducing the team's innovative achievements from the establishment of a clinical research system for individualized drug use and the establishment of a large data collection standard for dermatology and innovative skin diseases Internet Hospital ecosystem.
the second half of the conference was co-chaired by Professor Chen Xiang and Professor Wang Rexing of the First Affiliated Hospital of Anhui Medical University.
Professor Li Yuzhen of the Second Hospital affiliated with Harbin Medical University first shared the treatment of biopharmaceutical agents in psoriasis in special and incurable areas, including the efficacy of psoriasis in the scalp, psoriasis, genital and palm areas, and shared his clinical application experience.
Fuqiu Li of Jilin University Second Hospital summed up all the biological agents currently used in clinical applications to treat psoriasis, and put forward his own opinions on the rational choice of biological agents.
Professor Wang Honglin of Shanghai First People's Hospital, affiliated with Shanghai Jiaoda University, described the progress of research on the correlation between psoriasis and RNA virus infection, the differentiation of Th17 cells in key cells where small molecular compounds inhibit the onset of psoriasis, and the new prospect of interstitrinated stem cells in the treatment of psoriasis, bringing new research directions to the foundation and clinical research of psoriasis.
satellite will be presided over by Professor Yang Yanya from the Seventh Medical Center of the PLA General Hospital.
Professor Sun Liangdan of the First Affiliated Hospital of Anhui Medical University first shared data on the treatment of silver plaque psoriasis, psoriasis arthritis, psoriasis and psoriasis co-disease, while data from phase 3 clinical trials in China also showed that Skuchiyu monoantigen is a treatment plan more in line with the needs of patients with psoriasis in China.
Xuejun Zhang, Chairman of the Psoriasis Committee of the Chinese Medical Association's Dermatology Credit Union, shared the latest advances on IL-23 monoantials in the 2020 American Academy of Dermatology (AAD), the upstream regulatory factor for the core pathogenic pathogenesies of psoriasis. The team of the Institute of Dermatology of Anhui Medical University discovered the psoriasis coding mutation susceptible gene IL-23 through genome-wide exon sequencing, so as to develop the targeted biological agent Gusechiyu monoantigen, which showed good effectiveness and safety in the treatment of psoriasis, with a high clinical response rate and significantly improved the quality of life of psoriasis patients.
Professor Lu Yan of Jiangsu Provincial People's Hospital shared the characteristics of the rapid effectiveness and good safety shown by Ichizhu single resistance in the treatment of psoriasis, and further improved the treatment goal of psoriasis, reaching PSAI90 or even PASI100, providing a powerful weapon for doctors in the clinical cure of psoriasis.
this morning's academic conference, experts from basic research progress to specific treatment methods, from traditional diagnostic methods to the development of emerging drugs such as biologics, for delegates to provide a very important academic feast.
The speakers' in-depth and colorful reports were well received by the delegates, the atmosphere of the conference was warm, the applause was constantly psoriasis conference Source: Psoriasis Conference Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Metz Medicine" or "Source: MedSci Originals" are owned by Mets Medical, and are not authorized to be reproduced by any media, website or individual.
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here.